Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News CEL-SCI Corp CVM

Healthcare Biotechnology
CEL-SCI Corporation is a clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system. The Company is focused on the development of product candidates and technologies, such as Multikine, an investigational immunotherapy under development for the potential treatment of certain head and neck... see more

Recent & Breaking News (NYSEAM:CVM)

35 Stocks Moving In Friday's Mid-Day Session

Benzinga.com  November 23, 2018

CEL-SCI Receives about $8 Million from Warrant Exercises

Business Wire October 23, 2018

CEL-SCI Announces Warrants to Expire on October 11, 2018

Business Wire September 28, 2018

CEL-SCI Extends the Expiration Date of Series DD Warrants Issued in December 2016

Business Wire August 9, 2017

CEL-SCI Corporation Reports Third Quarter Fiscal Year 2017 Financial Results

Business Wire August 9, 2017

CEL-SCI Extends the Expiration Date of Series DD Warrants Issued in December 2016

Business Wire July 6, 2017

CEL-SCI Announces Reverse Stock Split

Business Wire June 12, 2017

CEL-SCI Announces New Data for Its Rheumatoid Arthritis Vaccine Candidate Published in Peer Reviewed Journal

Business Wire June 8, 2017

CEL-SCI Extends the Expiration Date of Series DD Warrants Issued in December 2016

Business Wire June 7, 2017

CEL-SCI Submits FDA Response for Its Phase 3 Head and Neck Cancer Trial

Business Wire June 5, 2017

Lifshitz & Miller LLP Announces Investigation of Akari Therapeutics, Plc, Alexion Pharmaceuticals, Inc., Amgen Inc., Cel-Sci Corp., Dick's Sporting Goods, Inc., Eco Science Solutions, Inc., Intra-Cellular Therapies, Inc. and Twilio Inc.

PR Newswire May 30, 2017

CEL-SCI Corporation Releases Letter to Shareholders

Business Wire May 24, 2017

CEL-SCI Scientist Presents at AAI - IMMUNOLOGY 2017 Meeting

Business Wire May 16, 2017

Biotech Stocks on Investors' Radar -- Merrimack Pharma, Amicus Therapeutics, CEL-SCI, and Cempra

PR Newswire April 6, 2017

Research Reports Initiation on Biotech Stocks -- Heat Biologics, PDL BioPharma, Achaogen, and CEL-SCI

PR Newswire February 16, 2017

12 Biggest Mid-Day Losers For Friday

Benzinga.com  December 23, 2016

CEL-SCI Announces Closing of Public Offereing and Receives Audit Opinion with Going Concern Explanation

Business Wire December 20, 2016

CEL-SCI Reports Fiscal 2016 Financial Results and Clinical & Corporate Developments

Business Wire December 14, 2016

CEL-SCI Reports on NYSE MKT Noncompliance Notice and Compliance Plan

Business Wire December 9, 2016

Mid-Afternoon Market Update: Crude Oil Up 1%; Five Below Shares Rise On Earnings Beat

Benzinga.com  December 2, 2016